Please try another search
For the fiscal year ended 31 December 2019, MD Biomedical Inc revenues decreased 52% to NT$37.4M. Net loss increased 34% to NT$65.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling Expense increase of 58% to NT$20M (expense), General and Administrative Expenses increase of 4% to NT$25.7M (expense).
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Revenue | 17.68 | 19.75 | 13.9 | 63.69 |
Gross Profit | -2.75 | -3.69 | -0.49 | 6.36 |
Operating Income | -32 | -33.09 | -27.72 | -22.16 |
Net Income | -34.06 | -31.55 | -28.22 | -20.64 |
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Assets | 115.25 | 148.2 | 186.63 | 208.67 |
Total Liabilities | 22.36 | 19.22 | 25.35 | 18.92 |
Total Equity | 92.89 | 128.99 | 161.28 | 189.75 |
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | -45.78 | -28.43 | -37.9 | -18.59 |
Cash From Investing Activities | -2.1 | -2.51 | -1.82 | 0.08 |
Cash From Financing Activities | -5.66 | -2.83 | -6.51 | -6.67 |
Net Change in Cash | -56.09 | -34.79 | -44.98 | -24.72 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review